Compare Heron Therapeutics Inc (HRTX) vs Snap On Incorporated (SNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Snap On Incorporated — how do they compare? Heron Therapeutics Inc trades at $0.35 (market cap $61.47M), while Snap On Incorporated trades at $408.11 (market cap $21.30B). The key difference: Snap On Incorporated is far larger — about 346.5× Heron Therapeutics Inc's market cap, and Snap On Incorporated pays a 2.37% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HRTX | SNA | |
|---|---|---|
Market Cap | $61.47M | $21.30B |
Sector | Health | Technology |
52-Week High | $1.49 | $419.31 |
52-Week Low | $0.32 | $321.38 |
Enterprise Value | $168.21M | $20.93B |
Dividend Yield | — | 2.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) trades at $0.3409, up 3.24% today, but faces bearish technical signals with 18 sell indicators versus 6 buys. The company reported Q2 2026 revenue of $37.7 million but missed earnings expectations with a $0.03 per share loss. Despite strong analyst support (94.7% buy ratings), fundamental challenges persist with negative net income margins and elevated EV/EBITDA of 34.03.
Investment outlook remains cautious due to consistent earnings misses and negative cash flow from operations. The primary opportunity lies in analyst optimism and potential product growth, while risks include ongoing profitability challenges and competitive pressures in the biotechnology sector.
Snap-on Incorporated (SNA) trades at $408.44, down 0.65% with a bullish technical outlook supported by moving averages. The company maintains strong fundamentals with 19.6% net income margin and 17.58% ROE, though valuation metrics appear elevated. Recent Q2 2026 earnings beat expectations with $4.96 EPS, while the $100 million Diesel Laptops acquisition expands diagnostics capabilities.
SNA offers steady growth potential with strong cash flow generation and consistent dividends, but faces integration risks from recent acquisitions and premium valuation concerns. Analyst consensus remains bullish with $455.33 price target, though execution on growth initiatives will be critical for sustaining momentum amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Snap On Incorporated
Snap-on Incorporated is a leading global innovator, manufacturer, and marketer of tools, equipment, diagnostics, repair information, and systems solutions for professional users. Its products are widely used in vehicle service and repair, as well as in other demanding industrial environments. The company is best known for its premium tool brand, often sold through a network of franchised mobile stores, and is a primary supplier to technicians in the transportation industry.
Read more on SNA →
